The largest project underway is Novo Nordisk’s $4.1 billion expansion in Johnston County ... Amgen is also growing its local ...

Once completed, the new facility will measure 833,000 square feet and have a footprint of 417,639 square feet ... The new facility will be adjacent to Novo Nordisk's 457,000-square-foot Clayton plant, ...

It’s been another busy year in Indiana health care and life sciences, with headlines nearly every week announcing another ...

With a Goldilocks economy and a bull market charging into a second year, 2024 shaped up to be a good year for investors. Now, ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for legal issues in China. One of these stocks has a stronger investment ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 8 unusual trades. Delving into the details, we found 50% of ...

Globally, Novo Nordisk holds 65% of the market for GLP-1 medicines by volume, which is a big part of the reason that it was able to generate trailing-12-month operating income of $17.2 billion.

Novo Nordisk recently announced results for a new weight loss candidate, CagriSema. Data from the trial underwhelmed investors, and Novo stock is down almost 20% on the news. However, investors ...